The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated massive profits, the lapse of its exclusive rights opened the door to cheaper versions, dramatically diminishing revenue. This creates a specific dilemma for pharmaceutical companies relying on comparable blockbuster med

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in revenue , its intellectual property lapse created a deluge of lower-priced alternatives , significantly impacting its dominance. While specific firms may attempt to capitalize on male sexual dysfu